Is there a risk of monopolies in the biotech industry?
Yes, there is a significant risk. The biotech industry is heavily patent-driven, and companies that hold key patents can effectively monopolize certain sectors. This monopoly can lead to price gouging, where lifesaving technologies are priced out of reach for all but the wealthiest individuals or countries. Such practices further exacerbate economic disparities and limit the democratization of scientific advancements.